FDA and the Importance of Confidentiality - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA and the Importance of Confidentiality
Recent news stories have reported that FDA scientists have been suspected of leaking confidential, commercial, and trade secret information to the media.


Pharmaceutical Technology
Volume 36, Issue 10, pp. 170, 169

The importance of confidentiality

In the recent situation reported in the media, the scientists questioned the approval of a premarket approval application supplement and clearance of certain 510(k) applications (1, 2). The scientists claimed that FDA senior managers in CDRH and the FDA Commissioner were corrupt and incompetent (1, 2). The scientists reportedly publicly disclosed company confidential, commercial, trade secret information to the media in airing their concerns regarding the decisions made to approve or clear certain medical devices for marketing (1, 2). It is surprising and disturbing that the FDA scientific reviewers leaked confidential commercial information to the press. FDA regulations are clear: if the existence of a premarket submission has not been publicly disclosed and the submitter requests that the intent to market a device remain confidential, provides a certification to the Commissioner requesting confidentiality, and complies with various provisions regarding the maintenance of such confidentiality, then FDA will not disclose the existence of a premarket notification. This relates to existence and the intent to market a medical device, which is evident by the submission of a 510(k) application. There are similar confidentiality provisions relating to investigational products, full and abbreviated new drug applications, biologic license applications, and premarket approval applications. The news media has reported not only the existence of the companies intent to market certain medical devices but appears to have received internal agency files, documents, and confidential commercial information from FDA reviewers (1, 2). It is disturbing that an FDA contractor also apparently inadvertently made accessible over its website a significant amount of sensitive FDA documents (1, 2).

Companies spend huge amounts of money generating data to support the approval of pharmaceuticals, biologics, and medical devices. Companies expect that FDA will keep this information confidential and will not disclose it to competitors or to the public while the review process is ongoing. Disclosure of confidential information prior to a company receiving marketing approval or clearance can cause significant economic harm. Competitors can get advance notice of the products under review and adjust their marketing plans for competing products. Competitors may also use this information to further develop their own products.

FDA staff, outside contractors, special government employees, advisory committee members, and others who have access to company confidential, commercial, and trade-secret information must take their obligation to keep such information confidential seriously. FDA staff and others should not make the decision to disclose confidential information to the media just because they may disagree with or are challenging the scientific judgment of their superiors. FDA staff must follow the procedures established to present differing views of scientific data and the conclusions drawn with respect to safety and efficacy. If certain members of the FDA review staff disagree with the decision to approve or clear a product, they can document such objections in writing. If the review staff question the approval decision because they believe it was not supported by the clinical data, the public safety is at risk, the review process was compromised, or that there was corruption or incompetence uncovered during the review process, there are procedures that can be utilized to report such allegations. Staff can always raise concerns with internal management structure at FDA, Health and Human Services, the Office of Special Counsel, the President's staff, or through Congress. When raising the concerns up the chain of command, staff are well advised to present their allegations and documentation to support their assertions in an organized, responsible manner.

Maintaining confidentiality

As part of routine procedure, companies identify the parts of their submission (e.g., 510(k), PMA, NDA, and ANDA) that are considered confidential, commercial, trade secret information. Prior to approval or clearance, FDA is obligated to maintain that confidentiality. How should the agency ensure this confidentiality? It has been suggested by the attorney representing the whistle blowers that FDA have different computers and systems for maintaining confidential information that do not have, for example, Internet access. This is an expensive option; therefore, FDA staff should be trained and reminded on a periodic basis of their responsibility and obligation to maintain the confidentiality of submissions. If FDA staff members feel compelled to discuss concerns with the media, they can have these discussions without disclosing confidential information.

In closing, members of the FDA staff must understand and appreciate their obligation to maintain the confidentiality of submissions and not disclose confidential, commercial, trade secret information to the media. There must also be checks and balances on the review process. FDA staff should be aware of and follow procedures for raising scientific concerns that can impact the public health and safety. Ultimately, the public must continue to have confidence that FDA is making sound decisions on the approval and clearance of products.

David L. Rosen, BS Pharm., JD, is co-chair of the Life Sciences Industry Team and an FDA Practice Group Leader at Foley & Lardner LLP.

References

1. S. Usdin, BioCentury, 20 (30), July 23, 2012.

2. E. Lichtblau and S. Shane, New York Times, July 14, 2012.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here